Ignite Creation Date:
2024-05-06 @ 11:11 AM
Last Modification Date:
2024-10-26 @ 12:41 PM
Study NCT ID:
NCT03456726
Status:
COMPLETED
Last Update Posted:
2022-12-16
First Post:
2018-03-06
Brief Title:
Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkins Lymphoma With EZH2 Gene Mutation
Sponsor:
Eisai Co Ltd
Organization:
Eisai Inc
Study Overview
Official Title:
A Phase 2 Study of Tazemetostat in Relapsed or Refractory B-cell Non-Hodgkins Lymphoma With EZH2 Gene Mutation
Status:
COMPLETED
Status Verified Date:
2021-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multicenter open-label Phase 2 study to assess the efficacy and safety of tazemetostat in participants with relapsed or refractory B-cell non-Hodgkins lymphoma NHL with EZH2 gene mutation
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None